Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/27/2011WO2011133479A2 Combination therapy with a proteasome inhibitor and a gallium complex
10/27/2011WO2011133475A2 Compositions and method for the treatment of multiple myeloma
10/27/2011WO2011133463A2 Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions
10/27/2011WO2011133447A1 Oxazole derivatives useful as modulators of faah
10/27/2011WO2011133444A1 Substituted pyrimidines
10/27/2011WO2011133424A2 Genetic amplification of iqgap1 in cancer
10/27/2011WO2011133388A1 Pyrrolopyridine inhibitors of kinases
10/27/2011WO2011133385A2 Novel ether-based compounds and their use
10/27/2011WO2011133370A1 Shelf stable pharmaceutical depot
10/27/2011WO2011133348A1 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
10/27/2011WO2011133346A1 Peripheral opioid agonists and peripheral opioid antagonists
10/27/2011WO2011133226A2 Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
10/27/2011WO2011133219A1 Topical drug delivery system with dual carriers
10/27/2011WO2011133217A1 Topical drug delivery system with dual carriers
10/27/2011WO2011133212A1 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
10/27/2011WO2011133210A2 A method treating breast cancer
10/27/2011WO2011133182A1 Modulators of 5-ht receptors and methods of use thereof
10/27/2011WO2011133180A1 Chemosensory receptor ligand-based therapies
10/27/2011WO2011133179A1 Compositions comprising enzyme-cleavable hydromorphone prodrug
10/27/2011WO2011133178A1 Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
10/27/2011WO2011133177A1 Local anesthetic emulsion compositions and methods of making and using the same
10/27/2011WO2011133151A1 Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof
10/27/2011WO2011133150A1 Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
10/27/2011WO2011133149A1 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
10/27/2011WO2011133142A1 Treatment of vhl-negative tumors
10/27/2011WO2011133052A2 Use of the modified polysaccharides for heparin neutralization
10/27/2011WO2011133039A2 Novel conjugates of cc-1065 analogs and bifunctional linkers
10/27/2011WO2011132967A2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
10/27/2011WO2011132966A2 Transdermal absorption preparation
10/27/2011WO2011132901A2 Novel benzamide derivatives
10/27/2011WO2011132831A1 Use of glutamine for prevention, treatment or diagnosis of depression
10/27/2011WO2011132826A1 Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
10/27/2011WO2011132718A1 Composition containing reduced coenzyme q10, and manufacturing and stabilising methods therefor
10/27/2011WO2011132713A1 Lipid membrane structure with nuclear transferability
10/27/2011WO2011132712A1 Novel hydroxamic acid derivative
10/27/2011WO2011132672A1 Method for stabilizing functional nucleic acids
10/27/2011WO2011132633A1 Substituted 5-hydroxypyrimidine-4-carboxamide compound
10/27/2011WO2011132435A1 Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
10/27/2011WO2011132201A1 A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent
10/27/2011WO2011132177A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them
10/27/2011WO2011132172A1 NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
10/27/2011WO2011132171A1 Nitric oxide releasing prodrugs of therapeutic agents
10/27/2011WO2011132161A2 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
10/27/2011WO2011132157A1 Oral sustained release formulation of huperzine a
10/27/2011WO2011132114A2 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment
10/27/2011WO2011132085A2 Methods and compositions for treating fibrosis
10/27/2011WO2011132084A2 Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
10/27/2011WO2011132048A1 Heteroaryl compounds as pde10a inhibitors
10/27/2011WO2011132017A1 Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators
10/27/2011WO2011132008A2 Controlled release pharmaceutical composition
10/27/2011WO2011131975A1 Microsomal prostaglandin e syntase-1 inhibitors
10/27/2011WO2011131947A2 A process for particle processing of active pharmaceutical ingredients
10/27/2011WO2011131926A1 Novel iminosugar combinations
10/27/2011WO2011131925A2 Osmium (ii) arene azo anti-cancer complexes
10/27/2011WO2011131816A1 Synthesis of oxoisoaporphine derivatives and the uses thereof as antimalarial agents
10/27/2011WO2011131765A2 Artificial tear emulsion
10/27/2011WO2011131749A1 New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
10/27/2011WO2011131748A2 Novel inhibitors
10/27/2011WO2011131741A1 Heterocyclic carboxylic acid amides as pdk1 inihibitors
10/27/2011WO2011131709A1 Furopyridine compounds and uses thereof
10/27/2011WO2011131705A1 Treatment of multiple sclerosis with masitinib
10/27/2011WO2011131697A1 Lysine specific demethylase-1 inhibitors and their use
10/27/2011WO2011131661A1 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
10/27/2011WO2011131636A1 Combined treatment of cancer with benzo[e]pyridoindoles and dna-damaging agents
10/27/2011WO2011131613A1 Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
10/27/2011WO2011131605A1 Production of atorvastatin low in ether impurities
10/27/2011WO2011131596A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
10/27/2011WO2011131593A1 Derivatives of nitrogen heterocycles, method for preparing same and use thereof in human therapy
10/27/2011WO2011131576A1 Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
10/27/2011WO2011131571A1 Pyrrazolopyridine derivatives
10/27/2011WO2011131441A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate)
10/27/2011WO2011131439A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates
10/27/2011WO2011131371A1 Lipid binding nucleic acids
10/27/2011WO2011131370A1 Melt-granulated fingolimod
10/27/2011WO2011131369A1 Fingolimod in the form of a solid solution
10/27/2011WO2011131348A1 Aliskiren in form of a solid dispersion
10/27/2011WO2011131347A1 Pramipexole-containing matrix tablet
10/27/2011WO2011131314A1 Combination of drugs with protein-binding prodrugs
10/27/2011WO2011131135A1 Heteroaryl (alkyl) dithiocarbamate compounds, preparation methods and uses thereof
10/27/2011WO2011131103A1 Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses
10/27/2011WO2011131102A1 Preparation method of lactone and use thereof
10/27/2011WO2011131034A1 4'-demethylepipodophyllotoxin derivative, preparation method and use thereof
10/27/2011WO2011131026A1 Furo[3, 2-g]chromene compounds and uses thereof
10/27/2011WO2011130921A1 Inhibitors of akt activity
10/27/2011WO2011130908A1 Substituted pyrimidines
10/27/2011WO2011130877A1 Crystalline form of methylprednisolone aceponate monohydrate and preparation methods thereof
10/27/2011WO2011130834A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
10/27/2011WO2011130817A1 Pharmaceutical formulation and method for reducing hepatotoxicity
10/27/2011WO2011130788A1 Combined method for improving the health of skin
10/27/2011WO2011130787A1 Method for improving the health of skin
10/27/2011WO2011103018A8 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
10/27/2011WO2011101865A3 Stable pharmaceutical compositions of clopidogrel for parenteral delivery
10/27/2011WO2011101456A3 Stabilized phenylcarbamate derivative in solid state
10/27/2011WO2011098437A3 Progesterone receptor antagonists
10/27/2011WO2011089529A4 Salicylate fatty acid derivatives
10/27/2011WO2011087713A3 Substituted hexahydrochromeno [3, 4 - b] pyrroles with affinity for the serotonin receptor (5-ht) family
10/27/2011WO2011086306A9 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
10/27/2011WO2011084455A3 Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
10/27/2011WO2011083998A3 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
10/27/2011WO2011081971A3 Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer
1 ... 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 ... 7860